Search

Your search keyword '"Kollmannsberger, C."' showing total 649 results
Start Over Author "Kollmannsberger, C."
649 results on '"Kollmannsberger, C."'

1. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Author

Fonseca, N.M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A.J., Kollmannsberger, C., Tolmeijer, S.H., Boerrigter, E., Mehra, N., Erp, N.P. van, Chi, K.N., Wyatt, Alexander W., Fonseca, N.M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A.J., Kollmannsberger, C., Tolmeijer, S.H., Boerrigter, E., Mehra, N., Erp, N.P. van, Chi, K.N., and Wyatt, Alexander W.

Abstract

Contains fulltext : 305250.pdf (Publisher’s version ) (Open Access)

Published
2024

3. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Author

Choueiri, T.K., Motzer, R.J., Rini, B.I., Haanen, J., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J.L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M.B., Pal, S.K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., and Albiges, L.

Published
2020
Full Text
View/download PDF

5. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

Author

Nehra, J., Bradbury, P. A., Ellis, P. M., Laskin, J., Kollmannsberger, C., Hao, D., Juergens, R. A., Goss, G., Wheatley-Price, P., Hotte, S. J., Gelmon, K., Tinker, A. V., Brown-Walker, P., Gauthier, I., Tu, D., Song, X., Khan, A., Seymour, Lesley, and Smoragiewicz, M.

Published
2020
Full Text
View/download PDF

6. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

Author

Grünwald, V., primary, McKay, R.R., additional, Buchler, T., additional, Masatoshi, E., additional, Park, S.H., additional, Takagi, T., additional, Zanetta, S., additional, Keizman, D., additional, Suárez, C., additional, Négrier, S., additional, Lee, J.L., additional, Santini, D., additional, Bedke, J., additional, Staehler, M., additional, Kollmannsberger, C., additional, Choueiri, T., additional, Motzer, R., additional, Burgents, J., additional, Okpara, C., additional, and Powles, T., additional

Published
2023
Full Text
View/download PDF

8. CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting

Author

Bou-Nehme Sawaya, G, primary, Dragomir, A, additional, Kollmannsberger, C, additional, Basappa, NS, additional, Kapoor, A, additional, Soulières, D, additional, Finelli, A, additional, Heng, DYC, additional, Wood, L, additional, Castonguay, V, additional, Canil, C, additional, Winquist, E, additional, Graham, J, additional, Bjarnason, GA, additional, Bhindi, B, additional, Lalani, AK, additional, Pouliot, F, additional, Breau, RH, additional, and Tanguay, S, additional

Published
2022
Full Text
View/download PDF

11. Kanzerogenität

Author

Bokemeyer, C., Kollmannsberger, C., Schmoll, Hans-Joachim, editor, Höffken, Klaus, editor, and Possinger, Kurt, editor

Published
2006
Full Text
View/download PDF

14. Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC).

Author

Maurice-Dror C., Fonseca N., Herberts C., Kwan E.M., Kollmannsberger C., Tu W., Khalaf D.J., Annala M., Schonlau E., Bernales C.Q., Donnellan G., Vergidis J., Noonan K., Finch D.L., Zulfiqar M., Stacy M., Wyatt A.W., Chi K.N., Maurice-Dror C., Fonseca N., Herberts C., Kwan E.M., Kollmannsberger C., Tu W., Khalaf D.J., Annala M., Schonlau E., Bernales C.Q., Donnellan G., Vergidis J., Noonan K., Finch D.L., Zulfiqar M., Stacy M., Wyatt A.W., and Chi K.N.

Abstract

Background: Deleterious alterations in tumor suppressor genes (TSGs) TP53, RB1, and PTEN are potential markers of small cell neuroendocrine prostate cancer (SCNP), and androgen receptor pathway inhibitor (ARPI) resistance. We examined the outcomes and clinical features of mCRPC patients (pts) harboring biallelic loss in 0, 1, 2 or all 3 TSGs. Method(s): We identified 210 consecutive mCRPC pts providing >=1 plasma cell-free DNA sample with >=20% circulating tumor DNA fraction (ctDNA%) during their mCRPC disease course. ctDNA% >=20% enabled sensitive characterization of biallelic TSG loss (including by homozygous deletions and mutation plus somatic loss-of-heterozygosity; LOH). Patient records were reviewed for baseline characteristics, SCNP histology, and presence of liver metastases. We investigated associations between TSG loss and the following clinical outcomes: PSA response (PSA decline >=50% (PSA50 RR)), progression free survival (PFS) on 1L therapy, and overall survival (OS) from 1L therapy. Result(s): Median follow-up was 16.5 months (range: 0.4-112.4) and OS event rate was 95%. Median age at 1L mCRPC was 71 years (range: 48-98). Most pts were ECOG PS 0-1 (79%) and 13% had liver metastases. 91% received ARPI for 1L mCRPC and 7% received ARPI for castration-sensitive disease. TP53 was primarily inactivated by somatic mutation plus LOH (90%), whereas RB1 (71%) and PTEN (86%) were more commonly inactivated by homozygous deletions. Compared to pts without evidence of biallelic TSG loss, pts with loss of 3 TSGs were significantly enriched for de-novo M1 disease (86 vs. 60%, p=0.05) and liver metastases (28.5 vs. 6.8%, p<0.05). Ten pts (4.7%) had histologically confirmed SCNP and provided ctDNA at time of SCNP diagnosis. Of these, 7 (70%) had biallelic loss of >=2 TSGs. For all pts receiving 1L therapy, loss of >=1 TSG(s) was associated with decreased OS (HR: 1.86, 95% CI: 1.40-2.48, p<0.01) and PFS (HR:1.74, 95% CI 1.29-2.34, p<0.01) compared to pts with no bialle

Published
2022

20. Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

Author

Escudier, B., primary, Tannir, N., additional, Mcdermott, D., additional, Burotto, M., additional, Choueiri, T., additional, Hammers, H., additional, Plimack, E., additional, Porta, C., additional, George, S., additional, Powles, T., additional, Donskov, F., additional, Gurney, H., additional, Kollmannsberger, C., additional, Grimm, M., additional, Tomita, Y., additional, Rini, B., additional, Mchenry, M., additional, Lee, C., additional, and Motzer, R., additional

Published
2021
Full Text
View/download PDF

24. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

Author

Grünwald, V., McKay, R.R., Buchler, T., Masatoshi, E., Park, S.H., Takagi, T., Zanetta, S., Keizman, D., Suárez, C., Négrier, S., Lee, J.L., Santini, D., Bedke, J., Staehler, M., Kollmannsberger, C., Choueiri, T., Motzer, R., Burgents, J., Okpara, C., and Powles, T.

Published
2023
Full Text
View/download PDF

27. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation

Author

Małyszko, J. Bamias, A. Danesh, F.R. Dębska-Ślizień, A. Gallieni, M. Gertz, M.A. Kielstein, J.T. Tesarova, P. Wong, G. Cheung, M. Wheeler, D.C. Winkelmayer, W.C. Porta, C. Abu-Alfa, A.K. Amer, H. Beutel, G. Chapman, J. Chen, X. Chudek, J. Cosmai, L. Danesi, R. De Stefano, F. Iseki, K. Jaimes, E.A. Jhaveri, K.D. Jurczyszyn, A. Kazancioğlu, R. Kitchlu, A. Kollmannsberger, C. Lahoti, A. Li, Y. Macía, M. Matsubara, T. Mitropoulos, D. Noiri, E. Perazella, M.A. Ronco, P. Rosner, M.H. Soler Romeo, M.J. Sprangers, B. Stadler, W.M. Stevens, P.E. Tesař, V. Torres da Costa e Silva, V. Vesole, D.H. Vijayan, A. Viklický, O. Workeneh, B.T. Yanagita, M. Zakharova, E. Conference Participants

Abstract

The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute kidney injury and CKD. On the other hand, emerging evidence from large observational registry analyses have consistently shown that cancer risk is increased by at least 2- to 3-fold in kidney transplant recipients, and the observed increased risk occurs not only in those who have received kidney transplants but also in those on dialysis and with mild- to moderate-stage CKD. The interactions between cancer and CKD have raised major therapeutic and clinical challenges in the management of these patients. Given the magnitude of the problem and uncertainties, and current controversies within the existing evidence, Kidney Disease: Improving Global Outcomes (KDIGO) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology to identify key management issues in nephrology relevant to patients with malignancy. This report covers the discussed controversies in kidney disease in hematological malignancies, as well as cancer after kidney transplantation. An overview of future research priorities is also discussed. © 2020 Kidney Disease: Improving Global Outcomes (KDIGO)

Published
2020

28. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer

Author

Porta, C. Bamias, A. Danesh, F.R. Dębska-Ślizień, A. Gallieni, M. Gertz, M.A. Kielstein, J.T. Tesarova, P. Wong, G. Cheung, M. Wheeler, D.C. Winkelmayer, W.C. Małyszko, J. Abu-Alfa, A.K. Amer, H. Beutel, G. Chapman, J. Chen, X. Chudek, J. Cosmai, L. Danesi, R. De Stefano, F. Iseki, K. Jaimes, E.A. Jhaveri, K.D. Jurczyszyn, A. Kazancioğlu, R. Kitchlu, A. Kollmannsberger, C. Lahoti, A. Li, Y. Macía, M. Matsubara, T. Mitropoulos, D. Noiri, E. Perazella, M.A. Ronco, P. Rosner, M.H. Soler Romeo, M.J. Sprangers, B. Stadler, W.M. Stevens, P.E. ladimír Tesař Torres da Costa e Silva, V. Vesole, D.H. Vijayan, A. Viklický, O. Workeneh, B.T. Yanagita, M. Zakharova, E.

Abstract

The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues in the setting of malignancy can worsen patient outcomes and diminish the adequacy of anticancer treatments. In addition, the oncology treatment landscape is changing rapidly, and data on tolerability of novel therapies in patients with CKD are often lacking. Caring for oncology patients has become more specialized and interdisciplinary, currently requiring collaboration among specialists in nephrology, medical oncology, critical care, clinical pharmacology/pharmacy, and palliative care, in addition to surgeons and urologists. To identify key management issues in nephrology relevant to patients with malignancy, KDIGO (Kidney Disease: Improving Global Outcomes) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology in December 2018. This report covers issues related to kidney impairment and solid organ malignancies as well as management and treatment of kidney cancer. Knowledge gaps, areas of controversy, and research priorities are described. © 2020 Kidney Disease:Improving Global Outcomes (KDIGO)

Published
2020

37. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

Author

Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claen, J., Cohn-Cedermark, G., Dahl, A. A., Daugaard, G., De Giorgi, U., De Santis, M., De Wit, M., De Wit, R., Dieckmann, K. P., Fenner, M., Fizazi, K., Flechon, A., Fossa, S. D., Germá Lluch, J. R., Gietema, J. A., Gillessen, S., Giwercman, A., Hartmann, J. T., Heidenreich, A., Hentrich, M., Honecker, F., Horwich, A., Huddart, R. A., Kliesch, S., Kollmannsberger, C., Krege, S., Laguna, M. P., Looijenga, L. H. J., Lorch, A., Lotz, J. P., Mayer, F., Necchi, A., Nicolai, N., Nuver, J., Oechsle, K., Oldenburg, J., Oosterhuis, J. W., Powles, T., Rajpert-De Meyts, E., Rick, O., Rosti, G., Salvioni, R., Schrader, M., Schweyer, S., Sedlmayer, F., Sohaib, A., Souchon, R., Tandstad, T., Winter, C., and Wittekind, C.

Published
2013
Full Text
View/download PDF

44. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial

Author

Bachner, M., Loriot, Y., Gross-Goupil, M., Zucali, P. A., Horwich, A., Germa-Lluch, J.-R., Kollmannsberger, C., Stoiber, F., Fléchon, A., Oechsle, K., Gillessen, S., Oldenburg, J., Cohn-Cedermark, G., Daugaard, G., Morelli, F., Sella, A., Harland, S., Kerst, M., Gampe, J., Dittrich, C., Fizazi, K., and De Santis, M.

Published
2012
Full Text
View/download PDF

47. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

Author

Albiges, L., primary, Tannir, N., additional, Burotto, M., additional, Mcdermott, D., additional, Plimack, E., additional, Barthélémy, P., additional, Porta, C., additional, Powles, T., additional, Donskov, F., additional, George, S., additional, Kollmannsberger, C., additional, Gurney, H., additional, Grimm, M., additional, Tomita, Y., additional, Castellano, D., additional, Rini, B., additional, Choueiri, T., additional, Shally Saggi, S., additional, Mchenry, M., additional, and Motzer, R., additional

Published
2020
Full Text
View/download PDF

48. 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Author

Albiges, L., primary, Tannir, N., additional, Burotto, M., additional, McDermott, D.F., additional, Plimack, E.R., additional, Barthélémy, P., additional, Porta, C.G., additional, Powles, T.B., additional, Donskov, F., additional, George, S., additional, Kollmannsberger, C., additional, Gurney, H., additional, Grimm, M-O., additional, Tomita, Y., additional, Castellano Gauna, D., additional, Rini, B.I., additional, Choueiri, T.K., additional, Saggi, S.S., additional, McHenry, M.B., additional, and Motzer, R.J., additional

Published
2020
Full Text
View/download PDF

50. Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma

Author

Wells, J.C., primary, Dudani, S., additional, Gan, C.L., additional, Stukalin, I., additional, Azad, A., additional, Liow, E., additional, Donskov, F., additional, Yuasa, T., additional, Pal, S., additional, De Velasco, G., additional, Wood, L., additional, Hansen, A., additional, Beuselinck, B., additional, Kollmannsberger, C., additional, Powles, T., additional, Mcgregor, B., additional, Duh, M.S., additional, Huynh, L., additional, and Heng, D.Y.C., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results